ATE510827T1 - Inhibitoren von proteinkinasen - Google Patents
Inhibitoren von proteinkinasenInfo
- Publication number
- ATE510827T1 ATE510827T1 AT08838451T AT08838451T ATE510827T1 AT E510827 T1 ATE510827 T1 AT E510827T1 AT 08838451 T AT08838451 T AT 08838451T AT 08838451 T AT08838451 T AT 08838451T AT E510827 T1 ATE510827 T1 AT E510827T1
- Authority
- AT
- Austria
- Prior art keywords
- diseases
- inhibitors
- protein kinases
- cyclin
- pain
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 108091007914 CDKs Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99882107P | 2007-10-12 | 2007-10-12 | |
| PCT/EP2008/063715 WO2009047359A1 (en) | 2007-10-12 | 2008-10-13 | Inhibitors of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE510827T1 true ATE510827T1 (de) | 2011-06-15 |
Family
ID=40227837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08838451T ATE510827T1 (de) | 2007-10-12 | 2008-10-13 | Inhibitoren von proteinkinasen |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8716296B2 (de) |
| EP (1) | EP2212297B1 (de) |
| JP (2) | JP5681855B2 (de) |
| KR (1) | KR20100090772A (de) |
| CN (2) | CN101889004B (de) |
| AT (1) | ATE510827T1 (de) |
| AU (1) | AU2008309517B2 (de) |
| BR (1) | BRPI0818543A2 (de) |
| CA (1) | CA2702008A1 (de) |
| DK (1) | DK2212297T3 (de) |
| EA (1) | EA020439B1 (de) |
| HK (1) | HK1203950A1 (de) |
| HR (1) | HRP20110470T1 (de) |
| IL (1) | IL204594A (de) |
| MX (1) | MX2010003987A (de) |
| NZ (1) | NZ584454A (de) |
| SI (1) | SI2212297T1 (de) |
| WO (1) | WO2009047359A1 (de) |
| ZA (1) | ZA201001910B (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2539568C2 (ru) | 2008-10-31 | 2015-01-20 | Дженентек, Инк. | Пиразолопиримидиновые соединения-ингибиторы jak и способы |
| WO2010053861A2 (en) * | 2008-11-07 | 2010-05-14 | H. Lundbeck A/S | Biologically active amides |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| EP2544686A4 (de) | 2010-02-05 | 2013-06-26 | Whitehead Biomedical Inst | Kombinationsverfahren zur behandlung einer krankheit |
| SG183192A1 (en) | 2010-03-10 | 2012-09-27 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| JP2013107824A (ja) * | 2010-03-17 | 2013-06-06 | Dainippon Sumitomo Pharma Co Ltd | 新規単環ピリミジン誘導体 |
| US9290499B2 (en) | 2010-05-19 | 2016-03-22 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| KR101995013B1 (ko) * | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
| US20130303507A1 (en) * | 2011-01-28 | 2013-11-14 | Novartis Ag | Substituted hetero-biaryl compounds and their uses |
| EP2561867A1 (de) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9-Hemmer zur Behandlung eines Mittellinienkarzinoms |
| EP2562265A1 (de) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Empfindlichkeit auf selektive CDK9-Inhibitoren |
| WO2013052417A1 (en) | 2011-10-03 | 2013-04-11 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
| US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
| US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| IN2014KN02601A (de) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| RU2014145121A (ru) | 2012-05-22 | 2016-07-10 | Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл | Пиримидиновые соединения для лечения злокачественной опухоли |
| EP2909211A4 (de) | 2012-10-17 | 2016-06-22 | Univ North Carolina | Pyrazolopyrimidinverbindungen zur krebsbehandlung |
| EP2925752A4 (de) | 2012-11-27 | 2016-06-01 | Univ North Carolina | Pyrimidinverbindungen zur krebsbehandlung |
| SMT202100687T1 (it) | 2013-03-12 | 2022-01-10 | Vertex Pharma | Inibitori della dna-pk |
| EP2970200A1 (de) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridin-cdk9-kinasehemmer |
| BR112015023013A2 (pt) | 2013-03-13 | 2017-07-18 | Abbvie Inc | inibidores de quinase cdk9 |
| US9073922B2 (en) | 2013-03-14 | 2015-07-07 | Abbvie, Inc. | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors |
| US9796708B2 (en) | 2013-03-14 | 2017-10-24 | Abbvie Inc. | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors |
| CN105189512A (zh) | 2013-03-14 | 2015-12-23 | 艾伯维公司 | 吡咯并嘧啶cdk9激酶抑制剂 |
| GB2513403A (en) * | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
| ES2705342T3 (es) | 2013-10-17 | 2019-03-22 | Vertex Pharma | Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK |
| US9328112B2 (en) | 2014-02-06 | 2016-05-03 | Abbvie Inc. | Tetracyclic CDK9 kinase inhibitors |
| WO2015157122A1 (en) * | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrazolopyrimidine compounds |
| PE20211782A1 (es) | 2014-05-23 | 2021-09-08 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos |
| EP3206749B1 (de) | 2014-10-14 | 2021-09-08 | The Regents of the University of California | Die cdk9- und brd4-hemmern flavopiridol und jq1 zur hemmung von knorpelentzündungen |
| WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| DK3539961T3 (da) | 2015-06-29 | 2022-01-03 | Astrazeneca Ab | Polycykliske amidderivativer som cdk9-inhibitorer |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| JP6954921B2 (ja) | 2016-04-07 | 2021-10-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としてのピリジル誘導体 |
| EP3518931A4 (de) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | Verfahren zur behandlung von krebs mit einer kombination aus dna-schädigenden substanzen und dna-pk-inhibitoren |
| EP3804724B1 (de) * | 2016-10-20 | 2022-12-07 | Pfizer Inc. | Cdk-inhibitoren zur behandlung von pah |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| MX388257B (es) | 2017-05-18 | 2025-03-19 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2. |
| EP3625223B1 (de) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidinderivate |
| RU2769696C2 (ru) | 2017-05-22 | 2022-04-05 | Ф. Хоффманн-Ля Рош Аг | Терапевтические соединения и композиции и способы их применения |
| US11149021B2 (en) * | 2017-05-24 | 2021-10-19 | Abbisko Therapeutics Co., Ltd. | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof |
| CA3159628A1 (en) * | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists and uses thereof |
| AU2020401999B2 (en) | 2019-12-09 | 2024-01-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
| RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
| WO2022197756A1 (en) * | 2021-03-17 | 2022-09-22 | Shire Human Genetic Therapies, Inc. | Plasma kallikrein inhibitors |
| WO2022257965A1 (zh) * | 2021-06-09 | 2022-12-15 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
| CN115703760B (zh) * | 2021-08-11 | 2024-05-31 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
| CN115703738B (zh) * | 2021-08-16 | 2024-06-21 | 中国科学院上海药物研究所 | 含2-芳杂环取代的脲类化合物、其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100521735B1 (ko) | 2000-02-25 | 2005-10-17 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 조절인자 |
| DE10114138C2 (de) | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
| DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2002094825A1 (en) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Novel spiropiperidine derivative |
| DE10129028A1 (de) | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| US20060293339A1 (en) | 2003-03-24 | 2006-12-28 | Chakravarty Prasun K | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
| GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
| AU2004261482A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
| EP1648875A1 (de) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidine als kinaseinhibitoren |
| EP1678147B1 (de) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmazeutisch wirksame 4,6-disubstituierte aminopyrimidinderivate als modulatoren von proteinkinasen |
| WO2005040135A1 (ja) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
| WO2005103022A1 (en) | 2004-04-20 | 2005-11-03 | Transtech Pharma, Inc. | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
| FR2878247B1 (fr) | 2004-11-19 | 2008-10-03 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| EP1901747A2 (de) * | 2005-05-25 | 2008-03-26 | Ingenium Pharmaceuticals AG | Cdk-inhibitoren auf pyrimidinbasis zur schmerzbehandlung |
-
2008
- 2008-10-13 CA CA2702008A patent/CA2702008A1/en not_active Abandoned
- 2008-10-13 JP JP2010528428A patent/JP5681855B2/ja not_active Expired - Fee Related
- 2008-10-13 KR KR1020107010451A patent/KR20100090772A/ko not_active Ceased
- 2008-10-13 AU AU2008309517A patent/AU2008309517B2/en not_active Ceased
- 2008-10-13 CN CN200880119493.3A patent/CN101889004B/zh not_active Expired - Fee Related
- 2008-10-13 US US12/226,286 patent/US8716296B2/en not_active Expired - Fee Related
- 2008-10-13 CN CN201410394966.8A patent/CN104151293A/zh active Pending
- 2008-10-13 AT AT08838451T patent/ATE510827T1/de not_active IP Right Cessation
- 2008-10-13 HR HR20110470T patent/HRP20110470T1/hr unknown
- 2008-10-13 SI SI200830286T patent/SI2212297T1/sl unknown
- 2008-10-13 MX MX2010003987A patent/MX2010003987A/es active IP Right Grant
- 2008-10-13 EA EA201000554A patent/EA020439B1/ru not_active IP Right Cessation
- 2008-10-13 DK DK08838451.6T patent/DK2212297T3/da active
- 2008-10-13 NZ NZ584454A patent/NZ584454A/en not_active IP Right Cessation
- 2008-10-13 WO PCT/EP2008/063715 patent/WO2009047359A1/en not_active Ceased
- 2008-10-13 EP EP08838451A patent/EP2212297B1/de not_active Not-in-force
- 2008-10-13 BR BRPI0818543A patent/BRPI0818543A2/pt not_active IP Right Cessation
-
2010
- 2010-03-17 ZA ZA2010/01910A patent/ZA201001910B/en unknown
- 2010-03-18 IL IL204594A patent/IL204594A/en not_active IP Right Cessation
-
2014
- 2014-05-05 US US14/269,703 patent/US20150038516A1/en not_active Abandoned
- 2014-09-03 JP JP2014178745A patent/JP2015038077A/ja active Pending
-
2015
- 2015-05-13 HK HK15104540.0A patent/HK1203950A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2212297T3 (da) | 2011-09-05 |
| US8716296B2 (en) | 2014-05-06 |
| IL204594A0 (en) | 2010-11-30 |
| EA201000554A1 (ru) | 2011-04-29 |
| EP2212297B1 (de) | 2011-05-25 |
| CN101889004A (zh) | 2010-11-17 |
| AU2008309517A1 (en) | 2009-04-16 |
| US20100249149A1 (en) | 2010-09-30 |
| EA020439B1 (ru) | 2014-11-28 |
| MX2010003987A (es) | 2010-08-04 |
| AU2008309517B2 (en) | 2013-03-14 |
| IL204594A (en) | 2013-12-31 |
| HRP20110470T1 (hr) | 2011-07-31 |
| CA2702008A1 (en) | 2009-04-16 |
| HK1203950A1 (en) | 2015-11-06 |
| NZ584454A (en) | 2011-09-30 |
| ZA201001910B (en) | 2011-05-25 |
| KR20100090772A (ko) | 2010-08-17 |
| US20150038516A1 (en) | 2015-02-05 |
| BRPI0818543A2 (pt) | 2018-10-23 |
| JP5681855B2 (ja) | 2015-03-11 |
| WO2009047359A1 (en) | 2009-04-16 |
| EP2212297A1 (de) | 2010-08-04 |
| HK1150052A1 (en) | 2011-10-28 |
| CN101889004B (zh) | 2014-09-10 |
| JP2011500539A (ja) | 2011-01-06 |
| CN104151293A (zh) | 2014-11-19 |
| SI2212297T1 (sl) | 2011-09-30 |
| JP2015038077A (ja) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE510827T1 (de) | Inhibitoren von proteinkinasen | |
| CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
| EA201170052A1 (ru) | Производные тиофена или тиазола и их применение как ингибиторов pi3k | |
| NO20081636L (no) | FAP - inhibitorer | |
| EA201270535A1 (ru) | Пуриновые производные, применимые в качестве ингибиторов hsp90 | |
| EA201001359A1 (ru) | Гетероциклические соединения в качестве ингибиторов cxcr2 | |
| EA200970738A1 (ru) | Ингибиторы активности akt | |
| EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
| EA201000100A1 (ru) | Гетероциклические соединения, полезные в качестве ингибиторов mk2 | |
| EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
| EA201170521A1 (ru) | Новые соединения | |
| EA200901212A1 (ru) | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний | |
| MX2012002542A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
| EA201070247A1 (ru) | Ингибиторы протеасом | |
| EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
| EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
| BR112012007747A2 (pt) | Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos | |
| ATE549336T1 (de) | Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer | |
| EA201201274A1 (ru) | Ингибиторы протеинкиназ | |
| ATE447559T1 (de) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| EA201100447A1 (ru) | Органические соединения | |
| DK1761520T3 (da) | Kinaseinhibitorer | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |